可变剪接在卵巢癌中的作用研究进展
Research Progress on the Role of Variable Splicing in Ovarian Cancer
DOI: 10.12677/ACM.2024.143812, PDF,   
作者: 冉黔川, 廖德仲*:贵州中医院大学基础医学院,贵州 贵阳
关键词: 可变剪接卵巢癌耐药精准治疗Alternative Splicing Ovarian Cancer Drug Resistance Precision Medicine
摘要: 卵巢癌(ovarian cancer, OC)是发生在卵巢的恶性肿瘤性疾病。卵巢癌大多发病隐匿,进展迅速,加之缺乏高效的早期诊断措施,许多病人初次诊断时已属晚期。在诊断和治疗方面已取得了一定的进展,但其五年生存率仍然低,所以迫切需要研究OC的发生和发展机制。中心法则中RNA是由DNA转录而来的,作为一个转录本来源的DNA转录区域却不一定是由某个连续DNA片段提供的,甚至可能有间隔DNA转录区的交叉,不同区域不同顺序的转录产物共同组成一个转录本,极大增加了DNA产生RNA的复杂度。人类基因组中多数基因都会发生RNA的可变剪接(alternative splicing, AS),AS可实现相同的前信使RNA生成多个mRNA剪接异构体和下游蛋白质亚型。一个基因的不同编码区可以以不同的方式剪接,导致该基因的多种转录状态,最终的蛋白产物可能具有不同的或相互拮抗的功能和结构特征。这在很大程度上扩大了人类基因的复杂性和多样性,影响着肿瘤细胞表型和信号通路,从而影响肿瘤的发生、发展。OC中也发现可变剪接事件,笔者就AS在OC中的作用作综述。
Abstract: Ovarian cancer (OC) is a malignant tumor disease that occurs in the ovaries. The incidence of ovari-an cancer is mostly hidden, rapid progress, coupled with the lack of efficient early diagnosis measures, many patients are in the late stage when they are diagnosed for the first time. Some pro-gress has been made in diagnosis and treatment, but the five-year survival rate is still low. There-fore, there is an urgent need to study the occurrence and development mechanism of OC. In the central rule, RNA is transcribed from DNA, but the DNA transcriptional region as a transcript source is not necessarily provided by a continuous DNA fragment, and there may even be intersecting DNA transcripts. Transcripts from different regions and different sequences form a transcript, which greatly increases the complexity of DNA to produce RNA. However, RNA alternative splicing (alter-native splicing, AS) occurs in most genes in the human genome, and AS can achieve the same pre-messenger that enables RNA to produce multiple mRNA splicing isomers and downstream protein subtypes. Different coding regions of a gene can be spliced in different ways, resulting in a variety of transcriptional states of the gene, and the final protein products may have different or mutually antagonistic functional and structural characteristics. This greatly expands the complexity and diversity of human genes and affects the phenotype and signal pathway of tumor cells, thus af-fecting the occurrence and development of tumors. Alternative splicing events are also found in OC. The author summarizes the role of AS in OC.
文章引用:冉黔川, 廖德仲. 可变剪接在卵巢癌中的作用研究进展[J]. 临床医学进展, 2024, 14(3): 1077-1082. https://doi.org/10.12677/ACM.2024.143812

参考文献

[1] Bonnal, S.C., López-Oreja, I. and Valcárcel, J. (2020) Roles and Mechanisms of Alternative Splicing in Can-cer—Implications for Care. Nature Reviews Clinical Oncology, 17, 457-474. [Google Scholar] [CrossRef] [PubMed]
[2] Zhang, S., Wu, X., Diao, P., et al. (2020) Identification of a Prognostic Alternative Splicing Signature in Oral Squamous Cell Carcinoma. Journal of Cellular Physiology, 235, 4804-4813. [Google Scholar] [CrossRef] [PubMed]
[3] Bernard, A., Boidot, R. and Végran, F. (2022) Alternative Splicing in Cancer and Immune Cells. Cancers, 14, Article No. 1726. [Google Scholar] [CrossRef] [PubMed]
[4] Chabot, B. and Shkreta, L. (2016) Defective Control of Pre-Messenger RNA Splicing in Human Disease. Journal of Cell Biology, 212, 13-27.
[5] David, C.J. and Manley, J.L. (2010) Alternative Pre-MRNA Splicing Regulation in Cancer: Pathways and Programs Unhinged. Genes & Development, 24, 2343-2364. [Google Scholar] [CrossRef] [PubMed]
[6] Ding, Y., Feng, G. and Yang, M. (2020) Prognostic Role of Alternative Splicing Events in Head and Neck Squamous Cell Carcinoma. Cancer Cell International, 20, Article No. 168. [Google Scholar] [CrossRef] [PubMed]
[7] Donoghue, M.T.A., Schram, A.M., Hyman, D.M., et al. (2020) Discovery through Clinical Sequencing in Oncology. Nature Cancer, 1, 774-783. [Google Scholar] [CrossRef] [PubMed]
[8] Wright, C.J., Smith, C.W.J. and Jiggins, C.D. (2022) Alternative Splicing as a Source of Phenotypic Diversity. Nature Reviews Genetics, 23, 697-710. [Google Scholar] [CrossRef] [PubMed]
[9] Murphy, A.J., Li, A.H., Li, P. and Sun, H. (2022) Therapeutic Targeting of Alternative Splicing: A New Frontier in Cancer Treatment. Frontiers in Oncology, 12, Article ID: 868664. [Google Scholar] [CrossRef] [PubMed]
[10] Lee, Y. and Rio, D.C. (2015) Mechanisms and Regulation of Al-ternative Pre-MRNA Splicing. Annual Review of Biochemistry, 84, 291-323. [Google Scholar] [CrossRef] [PubMed]
[11] Wang, S., Wang, S., Zhang, X., Meng, D., Xia, Q., Xie, S., Shen, S., Yu, B., Hu, J., Liu, H. and Yan, W. (2022) Comprehensive Analysis of Prognosis-Related Alternative Splicing Events in Ovarian Cancer. RNA Biology, 19, 1007-1018. [Google Scholar] [CrossRef] [PubMed]
[12] Gansler, T., Ganz, P.A., Grant, M., et al. (2010) Sixty Years of CA: A Cancer Journal for Clinicians. CA: A Cancer Journal for Clinicians, 60, 345-350. [Google Scholar] [CrossRef] [PubMed]
[13] Eisenhauer, E.A. (2017) Real-World Evidence in the Treatment of Ovarian Cancer. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 28, viii61-viii65. [Google Scholar] [CrossRef] [PubMed]
[14] Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. [Google Scholar] [CrossRef] [PubMed]
[15] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[16] Yao, S., Yuan, C., Shi, Y., Qi, Y., Sridha, R., Dai, M. and Cai, H. (2022) Alternative Splicing: A New Therapeutic Target for Ovarian Cancer. Technology in Cancer Research & Treatment, 21. [Google Scholar] [CrossRef] [PubMed]
[17] Hu, Z., Artibani, M., Alsaadi, A., et al. (2020) The Repertoire of Serous Ovarian Cancer Non-Genetic Heterogeneity Revealed by Single-Cell Sequencing of Normal Fallopian Tube Epi-thelial Cells. Cancer Cell, 37, 226-242. [Google Scholar] [CrossRef] [PubMed]
[18] Lheureux, S., Gourley, C., Vergote, I. and Oza, A.M. (2019) Epi-thelial Ovarian Cancer. The Lancet, 393, 1240-1253. [Google Scholar] [CrossRef
[19] Jeong, H.M., Han, J., Lee, S.H., Park, H.J., Lee, H.J., Choi, J.S., et al. (2017) ESRP1 Is Overexpressed in Ovarian Cancer and Promotes Switching from Mesenchymal to Epithelial Phenotype in Ovarian Cancer Cells. Oncogenesis, 6, E391. [Google Scholar] [CrossRef] [PubMed]
[20] Pereira, B., Billaud, M. and Almeida, R. (2017) RNA-Binding Proteins in Cancer: Old Players and New Actors. Trends in Cancer, 3, 506-528. [Google Scholar] [CrossRef] [PubMed]
[21] Hong, S. (2017) RNA Binding Protein as an Emerging Therapeutic Target for Cancer Prevention and Treatment. Journal of Cancer Prevention, 22, 203-210. [Google Scholar] [CrossRef
[22] Cretu, C., Schmitzova, J., Ponce-Salvatierra, A., Dybkov, O., De Laurentiis, E.I., Sharma, K., et al. (2016) Molecular Architecture of SF3b and Structural Consequences of Its Can-cer-Related Mutations. Molecular Cell, 64, 307-319. [Google Scholar] [CrossRef] [PubMed]
[23] Diao, Y., Li, Y., Wang, Z., Wang, S., Li, P. and Kong, B. (2022) SF3B4 Promotes Ovarian Cancer Progression by Regulating Alternative Splicing of RAD52. Cell Death & Disease, 13, 179. [Google Scholar] [CrossRef] [PubMed]
[24] Haferlach, T., et al. (2014) Landscape of Genetic Lesions in 944 Patients with Myelodysplastic Syndromes. Leukemia, 28, 241-247.
[25] Darman, R.B., et al. (2015) Can-cer-Associated SF3B1 Hotspot Mutations Induce Cryptic 3’ Splice Site Selection through Use of a Different Branch Point. Cell Reports, 13, 1033-1045. [Google Scholar] [CrossRef] [PubMed]
[26] Qian, Y., Chen, Y. and Li, X. (2021) CSF3R T618I, SETBP1 G870S, SRSF2 P95H, and ASXL1 Q780* Tetramutation Co-Contribute to Myeloblast Transformation in a Chronic Neutrophilic Leukemia. Annals of Hematology, 100, 1459-1461. [Google Scholar] [CrossRef] [PubMed]
[27] Obeng, E., Chappell, R., Seiler, M., et al. (2016) Physiologic Expression of Sf3b1K700E Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceo-some Modulation. Cancer Cell, 30, 404-417. [Google Scholar] [CrossRef] [PubMed]
[28] Shirai, C.L., Ley, J.N., White, B.S., et al. (2015) Mutant U2AF1 Expression Alters Hematopoiesis and Pre-MRNA Splicing in Vivo. Cancer Cell, 27, 631-643. [Google Scholar] [CrossRef] [PubMed]
[29] Wang, Z., Wang, S., Qin, J., Zhang, X., Lu, G., Liu, H., Guo, H., Wu, L., Shender, V.O., Shao, C., Kong, B. and Liu, Z. (2022) Splicing Factor BUD31 Promotes Ovarian Cancer Pro-gression through Sustaining the Expression of Anti-Apoptotic BCL2L12. Nature Communications, 13, Article No. 6246. [Google Scholar] [CrossRef] [PubMed]
[30] Wang, C.K., Chen, T.J., Tan, G.Y.T., Chang, F.P., Sridharan, S., Yu, C.A., Chang, Y.H., Chen, Y.J., Cheng, L.T. and Hwang-Verslues, W.W. (2023) MEX3A Mediates P53 Degrada-tion to Suppress Ferroptosis and Facilitate Ovarian Cancer Tumorigenesis. Cancer Research, 83, 251-263. [Google Scholar] [CrossRef
[31] Li, F., Zhao, C., Diao, Y., Wang, Z., Peng, J., Yang, N., Qiu, C., Kong, B. and Li, Y. (2022) MEX3A Promotes the Malignant Progression of Ovarian Cancer by Regulating In-tron Retention in TIMELESS. Cell Death & Disease, 13, Article No. 553. [Google Scholar] [CrossRef] [PubMed]
[32] Yoshida, K. and Miki, Y. (2010) Role of BRCA1 and BRCA2 as Regulators of DNA Repair, Transcription, and Cell Cycle in Response to DNA Damage. Cancer Science, 95, 866-871. [Google Scholar] [CrossRef] [PubMed]
[33] Li, Y., Chen, Z., Peng, J., Yuan, C., Yan, S., Yang, N., Li, P. and Kong, B. (2023) The Splicing Factor SNRPB Promotes Ovarian Cancer Progression through Regulating Ab-errant Exon Skipping of POLA1 and BRCA2. Oncogene, 42, 2386-2401. [Google Scholar] [CrossRef] [PubMed]
[34] Wang, S., Wang, Z., Li, J., Qin, J., Song, J., Li, Y., et al. (2021) Splicing Factor USP39 Promotes Ovarian Cancer Malignancy through Maintaining Efficient Splicing of Oncogenic HMGA2. Cell Death & Disease, 12, Article No. 294. [Google Scholar] [CrossRef] [PubMed]
[35] Hsu, K.F., Shen, M.R., Huang, Y.F., Cheng, Y.M., Lin, S.H., Chow, N.H., et al. (2015) Overexpression of the RNA- Binding Proteins Lin28B and IGF2BP3 (IMP3) Is Associated with Chemoresistance and Poor Disease Outcome in Ovarian Cancer. British Journal of Cancer, 113, 414-424. [Google Scholar] [CrossRef] [PubMed]
[36] Pellarin, I., Dall’Acqua, A., Gambelli, A., Pellizzari, I., D’Andrea, S., Sonego, M., et al. (2020) Splicing Factor Proline- and Glutamine-Rich (SFPQ) Protein Regulates Platinum Response in Ovarian Cancer-Modulating SRSF2 Activity. Oncogene, 39, 4390-4403. [Google Scholar] [CrossRef] [PubMed]
[37] Zhao, L., Wang, W., Huang, S., Yang, Z., Xu, L., Yang, Q., et al. (2018) The RNA Binding Protein SORBS2 Suppresses Metastatic Colonization of Ovarian Cancer by Stabilizing Tu-mor-Suppressive Immunomodulatory Transcripts. Genome Biology, 19, Article No. 35. [Google Scholar] [CrossRef] [PubMed]
[38] Zhang, D., Zou, D., Deng, Y. and Yang, L. (2021) Systematic Analysis of the Relationship between Ovarian Cancer Prognosis and Alternative Splicing. Journal of Ovarian Research, 14, Article No. 120. [Google Scholar] [CrossRef] [PubMed]
[39] Yin, H., Wang, J., Li, H., Yu, Y., Wang, X., Lu, L., Lv, C., Chang, B., Jin, W., Guo, W., et al. (2021) Extracellular Matrix Protein-1 Secretory Isoform Promotes Ovarian Cancer through Increasing Alternative MRNA Splicing and Stemness. Nature Communications, 12, Article No. 4230. [Google Scholar] [CrossRef] [PubMed]
[40] Marima, R., Francies, F.Z., Hull, R., Molefi, T., Oyomno, M., Khanyile, R., Mbatha, S., Mabongo, M., Owen Bates, D. and Dlamini, Z. (2021) MicroRNA and Alternative MRNA Splicing Events in Cancer Drug Response/Resistance: Potent Therapeutic Targets. Biomedicines, 9, Article No. 1818. [Google Scholar] [CrossRef] [PubMed]
[41] 陈延君, 刘晓菲, 刘涵, 等. 中医药干预肿瘤相关巨噬细胞极化治疗乳腺癌的研究进展[J]. 中国现代普通外科进展, 2023, 26(9): 741-744.